Oncolytic Adenoviruses for Cancer Therapy
Open Access
- 3 March 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5), 2517
- https://doi.org/10.3390/ijms22052517
Abstract
Many immuno-therapeutic strategies are currently being developed to fight cancer. In this scenario, oncolytic adenoviruses (Onc.Ads) have an interesting role for their peculiar tumor selectivity, safety, and transgene-delivery capability. The major strength of the Onc.Ads is the extraordinary immunogenicity that leads to a strong T-cell response, which, together with the possibility of the delivery of a therapeutic transgene, could be more effective than current strategies. In this review, we travel in the adenovirus (Ads) and Onc.Ads world, focusing on a variety of strategies that can enhance Onc.Ads antitumoral efficacy, passing through tumor microenvironment modulation. Onc.Ads-based therapeutic strategies constitute additional weapons in the fight against cancer and appear to potentiate conventional and immune checkpoint inhibitors (ICIs)-based therapies leading to a promising scenario.This publication has 96 references indexed in Scilit:
- Adenoviral Gene Transfer of PLD1-D4 Enhances Insulin Sensitivity in Mice by Disrupting Phospholipase D1 Interaction with PED/PEA-15PLOS ONE, 2013
- Gut microbiota-derived propionate reduces cancer cell proliferation in the liverBritish Journal of Cancer, 2012
- Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic AdenovirusCancer Research, 2012
- Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in PatientsCancer Research, 2012
- In vivoandin vitrodistribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartmentsAnnals of Medicine, 2011
- Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor GrowthMolecular Therapy, 2010
- In situ adenovirus vaccination engages T effector cells against cancerVaccine, 2009
- From the first to the third generation adenoviral vector: What parameters are governing the production yield?Biotechnology Advances, 2009
- Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-LCancer Gene Therapy, 2004
- Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat modelClinical Endocrinology, 2003